key: cord-0771932-bns5eb1t
authors: Finsterer, Josef; Korn, Maria
title: Aphasia seven days after second dose of an mRNA-based SARS-CoV-2 vaccine
date: 2021-06-24
journal: Brain Hemorrhages
DOI: 10.1016/j.hest.2021.06.001
sha: ec92f3e1a944de9969144463896bc5157ba232a2
doc_id: 771932
cord_uid: bns5eb1t

OBJECTIVES: Though rare, neurological side effects of SARS-CoV-2 vaccinations are increasingly reported. Even if the first dosage goes uncomplicated, the second dose may be complicated by severe adverse reactions as in the following case. Case report: A 52yo male developed sudden-onset reading difficulty and aphasia 7d after the second dose of an mRNA-based SARS-CoV-2 vaccine. He had a previous history of myocardial infarction, arterial hypertension, hyperlipidemia, and nephrolithiasis. Blood pressure was slightly elevated on admission. Blood tests revealed mildly elevated D-dimer, pre-diabetes and hyperuricemia. Cerebral magnetic resonance imaging revealed an intracerebral bleeding (ICB) in the left temporal lobe. Aphasia resolved almost completely within a few days. Blood pressure values were normal throughout hospitalisation. Whether there was a causal relation between the ICB and the vaccination remains speculative but cannot be definitively excluded. CONCLUSIONS: a second dose of a SARS-CoV-2 vaccination may be followed by ICB. Though the pathophysiology of ICB remains unexplained a causal relation between ICB and the vaccination cannot be excluded. Risk factors for ICB should be carefully monitored in patients undergoing SARS-CoV-2 vaccination.

Conflict of interest: The authors declare that they have no conflict of interest.

Ethical approval: All procedures performed in the studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent: Informed consent was obtained from all individual participants included in the study.

Corresponding author: 3 Abstract Objectives: Though rare, neurological side effects of SARS-CoV-2 vaccinations are increasingly reported. Even if the first dosage goes uncomplicated, the second dose may be complicated by severe adverse reactions as in the following case. Case report: A 52yo male developed sudden-onset reading difficulty and aphasia 7d after the second dose of an mRNA-based SARS-CoV-2 vaccine. He had a previous history of myocardial infarction, arterial hypertension, hyperlipidemia, and nephrolithiasis. Blood pressure was slightly elevated on admission. Blood tests revealed mildly elevated D-dimer, pre-diabetes and hyperuricemia. Cerebral magnetic resonance imaging revealed an intracerebral bleeding (ICB) in the left temporal lobe. Aphasia resolved almost completely within a few days. Blood pressure values were normal throughout hospitalisation. Whether there was a causal relation between the ICB and the vaccination remains speculative but cannot be definitively excluded. Conclusions: a second dose of a SARS-CoV-2 vaccination may be followed by ICB. Though the pathophysiology of ICB remains unexplained a causal relation between ICB and the vaccination cannot be excluded. Risk factors for ICB should be carefully monitored in patients undergoing SARS-CoV-2 vaccination.

Key words: intracerebral bleeding, SARS-CoV-2, COVID-19, aphasia, side effect, adverse reaction, vaccination 4 Letter to the Editor Though vaccination against SARS-CoV-2 is usually well tolerated, some patients experience side effects, including neurological adverse reactions [1] . Neurological adverse reactions to SARS-CoV-2 vaccinations include exacerbation or new onset neuro-immunologic disease, such as myasthenia, Guillain-Barre syndrome, immune encephalitis, or multiple sclerosis [2] but also ischemic stroke, or intra-cerebral bleeding (ICB). ICB may be due to hypocoagulability or immune-mediated thrombotic thrombocytopenia [3, 4] . Even if patients do not experience side effects after the first dosage, they may develop severe neurological complications after the second dose, as in the following case. The patient is a 52yo non-smoking, HIV-negative male, who experienced sudden-onset difficulties with reading and speaking seven days after the second dose of an mRNA-based SARS-CoV-2 vaccine. He did not experience any side effects immediately after the first or second vaccination. His previous history was positive for myocardial infarction four months earlier treated with stent implantation into the left anterior descending, ramus circumflexus, and right coronary artery, arterial hypertension, hyperlipidemia, and nephrolithiasis. Myocardial infarction was complicated by systolic dysfunction and non-sustained (persistent) ventricular tachycardias being treated with a temporary life west. His current medication comprised sacubitril/valsartan, atorvastatin, bisoprolol, and acetyl-salicylic acid. Neurologic exam one day later (hospital day (hd)-1) revealed motor aphasia with paraphasias and a spontaneous Babinski sign on the right side. Blood pressure was 170/98mmHg on admission. Blood tests were unremarkable except for slightly elevated D-dimer, hyperuricemia, and a HbA1c value of 5.8 (n, 4.0-5.7). The glucose tolerance test was indicative of pre-diabetes. Other coagulation parameters and the thrombocyte count were within normal limits. Cerebral MRI revealed a lobar bleeding in the left temporal lobe (figure 1). Cerebral CT angiography was normal. Aphasia resolved almost completely within a few days. On hd4 he was transferred to the rehabilitation unit with a therapy of sacubtril/valsartan, atorvastatin, and bisoprolol. The presented patient is interesting for ICB shortly after the second dose of an mRNA-based SARS-CoV-2 vaccine. Whether there was a causal relation between vaccination and the ICB remains speculative. Arguments for a causal relation are that ICB has been reported as a complication of a SARS-CoV-2 vaccination [5, 6] , that ICB occurred time-linked to the vaccination, and that arterial hypertension can be a complication of a SARS-CoV-2 vaccination [7] . A further argument in favour of a causal relation is that ICB has been 5 repeatedly reported as a complication of infections with SARS-CoV-2 [8] . Whether the slightly elevated D-dimer indicates hypercoagulability followed by compensatory hypocoagulability remains speculative. Pathophysiological mechanisms explaining SARS-CoV-2 associated ICB could be endothelial cell dysfunction due to direct invasion of the virus, vaccination induced thrombocytopenia, hypocoagulability due to disseminated intravascular coagulopathy or increased fibrinolysis [9] , or arterial hypertension due to affection of the autonomic innervation of the heart, Arguments against a causal relation are that the patient also had slightly elevated arterial hypertension on admission, that the latency between vaccination and ICB was 7 days, and that ICB after SARS-CoV2 vaccination has been only rarely reported. Possibly, the vaccination increased systolic blood pressure, or caused immune-mediated thrombocytopenia or hypocoagulability. An argument against the 7 day latency is that the T-cell response to the vaccination peaks not earlier than 14 days after vaccination [10] . This case shows that the second dose of a mRNA-based SARS-CoV-2 vaccine may be followed by ICB. Though the pathophysiology of ICB remains unexplained a causal relation between ICB and the vaccination cannot be excluded. Infectiologists and neurologists should remain vigilant for complications of SARS-CoV-2 vaccination. Risk factors for ICB should be carefully monitored in patients undergoing SARS-CoV-2 vaccination 

SARS-CoV-2 vaccines are not free of neurological side effects

Immune-Mediated Disease Flares or New-Onset Disease in 27 Subjects Following mRNA/DNA SARS-CoV-2 Vaccination. Vaccines (Basel)

Antibody-mediated procoagulant platelets in SARS-CoV-2-vaccination associated immune thrombotic thrombocytopenia

Secondary immune thrombocytopenia supposedly attributable to COVID-19 vaccination

Fatal cerebral haemorrhage after COVID-19 vaccine

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

Stage III Hypertension in Patients After mRNA-Based SARS-CoV-2 Vaccination

Intracerebral Hemorrhage in Patients With COVID-19: An Analysis From the COVID-19 Cardiovascular Disease Registry

Thromboelastography-Guided Anticoagulant Therapy for the Double Hazard of Thrombohemorrhagic Events in COVID-19: A Report of 3 Cases

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial